Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 12;23(4):661-676.
doi: 10.1093/neuonc/noaa233.

Population-based estimates of survival among elderly patients with brain metastases

Nayan Lamba  1 , Rachel Brigell Kearney  1 , Paul J Catalano  2 , Michael J Hassett  3 , Patrick Y Wen  4 , Daphne A Haas-Kogan  1 , Ayal A Aizer  1
Affiliations

Population-based estimates of survival among elderly patients with brain metastases

Nayan Lamba et al. Neuro Oncol. .

Abstract

Background: Prognostic estimates for patients with brain metastases (BM) stem from younger, healthier patients enrolled in clinical trials or databases from academic centers. We characterized population-level prognosis in elderly patients with BM.

Methods: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified 9882 patients ≥65 years old with BM secondary to lung, breast, skin, kidney, esophageal, colorectal, and ovarian primaries between 2014 and 2016. Survival was assessed by primary site and evaluated with Cox regression.

Results: In total, 2765 versus 7117 patients were diagnosed with BM at primary cancer diagnosis (synchronous BM, median survival = 2.9 mo) versus thereafter (metachronous BM, median survival = 3.4 mo), respectively. Median survival for all primary sites was ≤4 months, except ovarian cancer (7.5 mo). Patients with non-small-cell lung cancer (NSCLC) receiving epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-based therapy for synchronous BM displayed notably better median survival at 12.5 and 20.1 months, respectively, versus 2.8 months exhibited by other patients with NSCLC; survival estimates in melanoma patients based on receipt of BRAF/MEK therapy versus not were 6.7 and 2.8 months, respectively. On multivariable regression, older age, greater comorbidity, and type of managing hospital were associated with poorer survival; female sex, higher median household income, and use of brain-directed stereotactic radiation, neurosurgical resection, or systemic therapy (versus brain-directed non-stereotactic radiation) were associated with improved survival (all P < 0.05).

Conclusions: Elderly patients with BM have a poorer prognosis than suggested by prior algorithms. If prognosis is driven by systemic and not intracranial disease, brain-directed therapy with potential for significant toxicity should be utilized cautiously.

Keywords: Medicare; brain metastases; population; prognosis; survival.

PubMed Disclaimer

Comment in

References

    1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48–54. - PubMed
    1. Achrol AS, Rennert RC, Anders C, et al. . Brain metastases. Nat Rev Dis Primers. 2019;5(1):5. - PubMed
    1. Gaspar L, Scott C, Rotman M, et al. . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–751. - PubMed
    1. Sperduto PW, Chao ST, Sneed PK, et al. . Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655–661. - PubMed
    1. Kavouridis VK, Harary M, Hulsbergen AFC, et al. . Survival and prognostic factors in surgically treated brain metastases. J Neurooncol. 2019;143(2):359–367. - PubMed